Your occupation is quite impressive, so tell me, tell me, uh, your education and your, and your occupation.

Uh, yeah.

I was, I was a math major originally, um, and I studied, uh, for a, for a master's in computational biology at, uh, the University of Cambridge.

Um, and then I went on to do a PhD at Oxford in, uh, statistical genetics, so that kind of became my life's work.

Um, I also lived in Iceland for a year as well, working there on, on the genetic data they have in Iceland.

Um, and then, yeah, I was offered a position.

Uh, it was originally at USC.

Uh, obviously you had a few symptoms right before or you wouldn't have gone in to be tested, but was this, you know, uh, uh, d- was there any indication before?

Do you wanna, you wanna mention that a little bit?

Yes.

Well, I, I blame Augie Kung entirely for that actually.

Uh, it is his fault in a way that, that I went down this path, 'cause before, before that, before I met Augie, I wasn't really that...

I, I'd always been interested in these slightly more controversial topics like, why is-- why do some people get more education than others? Why are some people smarter than others? But I hadn't, it hadn't really been a focus of my research.

Actually, during my PhD with Peter Donnelly, I'd been working on much more standard sort of biomedical human genetics questions, like looking at BMI.

I, I was looking at, uh, developing methods for figuring out gene-environment interactions affecting BMI, which they do s- like, that's one kind of interaction that does seem to be real.

Just I'd love to hear anything that you wanna share with us.

A- anytime you involve large amounts of venture capital, then, then, um, people have various growth expectations and, and, uh, decisions get made that maybe wouldn't be in the long-term interests of, of patients.

Yeah.

I mean, I think that's a, that's certainly a risk, but there is, you know, there is a lot of demand for this product and, and, and, and I think that, uh, we're still in the sort of infancy and part of, part of the, um, part of, part of what's holding this industry back is we kind of need more, we need more money to be put into it.

We need more awareness of the potential of this technology and, uh, you know, Heracyte, their, their, their revenue's been growing pretty well.

They're trying to do a big raise this year.

Um, I think that there could be kind of a preference cascade here.

Like, a lot of the people that have been, uh, a lot of the customers so far have been, uh, you know, people from the tech world, people that are quite wealthy, and I think that's gonna create a lot of demand, um, as, as people see, uh, as people see these, these wealthy and sort of elite people, um, take-- uh, uh, wanting these services, then I think everyone else is gonna want them.

Yeah, yeah, yeah.